학술논문

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1
Document Type
Article
Source
HIV Research & Clinical Practice; Dec2020, Vol. 21 Issue 6, p151-167, 17p
Subject
EMTRICITABINE
RITONAVIR
DRUG efficacy
HIV
DARUNAVIR
TENOFOVIR
EMERALDS
CD4 lymphocyte count
Language
ISSN
25787489
Abstract
Copyright of HIV Research & Clinical Practice is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)